|Articles|November 18, 2003
FDA approves CrystaLens, first accommodating IOL
Eyeonics inc. (formerly C&C Vision) received FDA approval to marketthe CrystaLens, the first accommodating IOL that allows patients to focusautomatically and seamlessly at all distances.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
2
Q&A: Optimizing the ocular surface for light adjustable lens technology
3
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
4
PRIMA System: A major step in the battle against GA
5
























